



ISW/1618

MAIL STOP - PCT
Docket No.: 27242U
Attorneys: GMN/SMH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: AFARGAN et al.

Art Unit: UNKNOWN

Appl. No.: 10/568,144

Examiner: UNKNOWN

Appl. Filing Date: February 13, 2006

Confirmation No.: UNKNOWN

Intl. Appl. No.: PCT/IL2006/00017

Intl. Appl. Filing Date: 5 January 2006 (05.01.2006)

For: **GASTRO-RETENTIVE DIAGNOSTIC ASSEMBLIES**

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:


5. Information Disclosure Statement;
6. PTO Form-1449 citing 13 references; and
7. Copies of 12 of the 13 cited references.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,
THE NATH LAW GROUP

March 20, 2007

THE NATH LAW GROUP
112 South West Street
Alexandria, VA 22314



Gary M. Nath, Reg. No. 26,965
Susanne M. Hopkins, Reg. No. 33,247
Customer No. 20529

ct

5



MAIL STOP - PCT
Docket No.: 27242U
Attorneys: GMN/SMH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: AFARGAN et al. Art Unit: UNKNOWN
Appl. No.: 10/568,144 Examiner: UNKNOWN
Appl. Filing Date: February 13, 2006 Confirmation No.: UNKNOWN
Intl. Appl. No.: PCT/IL2006/00017
Intl. Appl. Filing Date: 5 January 2006 (05.01.2006)
For: **GASTRO-RETENTIVE DIAGNOSTIC ASSEMBLIES**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

a. ☒ The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

b. ☐ The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed statement is accompanied by [check one]:

- ☐ i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or
☐ ii. a check in the amount required by 37 C.F.R. 1.17(p).

c. ☐ The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

- ☐ Certification report(e) below; and
☐ a check in the amount as required by 1.17(p).

- d. ☐ The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.
- e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]
- ☐ I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,
- or
- ☐ I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- or
- ☐ Appropriate certification is attached.
- f. [XXX] If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.
- g. [XXX] Copies of the documents are attached herewith with a completed PTO Form-1449.
- or
- ☐ Copies of the documents are not attached, with a completed PTO Form-1449 as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:
- and / or
- [XXX] Copies of US Patents/Publications not attached, with a completed PTO Form-1449 as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

MAIL STOP - PCT
Docket No.: 27242U
Attorneys: GMN/SMH


The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
THE NATH LAW GROUP

March 20, 2007

THE NATH LAW GROUP
112 South West Street
Alexandria, VA 22314



Gary M. Nath, Reg. No. 26,965
Susanne M. Hopkins, Reg. No. 33,247
Customer No. 20529

ct



PTO Form-1449
INFORMATION
DISCLOSURE CITATION

In re Application of:
AFARGAN et al.

Application No:
10/568,144

Filing Date
February 13, 2006

Intl. Application No:
PCT/IL2006/00017

Intl. Filing Date:
05 January 2006 (05.01.2006)

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Issue / Publication Date	Inventor	Filed
	A1	6,685,962	03 Feb 2004	Friedman et al.	29 May 2002
	A2				

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Publication Date	Country	Translation
	A3	0 415 671	06 Mar 1991	EP	N/A
	A4	0 202 159	20 Nov 1986	EP	N/A
	A5				

OTHER

Examiner Initial		(Including Author, Title, Date, Pertinent Pages, etc.)
	A6	Chou et al., "MRI Manifestations of Gastrointestinal Lymphoma." <u>Abdominal Imaging</u> , 19:495-500, 1994.
	A7	Steingoetter et al., "Magnetic Resonance Imaging for the <i>in Vivo</i> Evaluation of Gastric-Retentive Tablets." <u>Pharmaceutical Research</u> , 20:12, pp.2001-2007, 2003.
	A8	Steingoetter et al., "Analysis of the Meal-Dependant Intragastic Performance of a Gastric-Retentive Tablet Assessed by Magnetic Resonance Imagine." <u>Aliment Pharmacology Therapy</u> , 18:713-720, 2003.
	A9	Shalaby et al., "Use of Ultrasound Imagine and Fluoroscopic Imaging to Study Gastric Retention of Enzyme-Digestible Hydrogels." <u>Biomaterials</u> , 13:5, pp.289-296, 1992.
	A10	Kagan et al., "Gastroretentive Accordion Pill: Enhancement of Riboflavin Bioavailability in Humans." <u>Journal of Controlled Release</u> , 113:208-215, 2006.
	A11	Chou et al., "MRI Manifestations of Gastrointestenstinal Wall Thickening." <u>Abdominal Imaging</u> , 19:389-394, 1994.
	A12	Shi et al., "Localization of Neuroendocrine Tumours with [¹¹ In]DTPA-Octreotide Scintigraphy (Octreoscan): A Comparative Study with CT and MR Imaging." <u>Q.J. Med.</u> , 91:295-301, 1998.
	A13	Ha et al., "Application of MRI for Small Intestinal Diseases." <u>Journal of Magnetic Resonance Imaging</u> , 8:375-383, 1998.
	A14	Madsen et al., "Magnetic Resonance Imaging of Crohn Disease: Early Recognition of Treatment Response and Relapse." <u>Abdominal Imaging</u> , 22:164-166, 1997.
	A15	Van Beers et al., "MRI of Complicated Anal Fistulae: Comparison with Digital Examination." <u>Journal of Computer Assisted Tomography</u> , 18:1, pp.87-90, 1994.

Examiner	Date Considered
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.